Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Myofibroblast YAP/TAZ activation is a key step in organ fibrogenesis
Xiaolin He, Monica F. Tolosa, Tianzhou Zhang, Santosh Kumar Goru, Luisa Ulloa Severino, Paraish S. Misra, Caitríona M. McEvoy, Lauren Caldwell, Stephen G. Szeto, Feng Gao, Xiaolan Chen, Cassandra Atin, Victoria Ki, Noah Vukosa, Catherine Hu, Johnny Zhang, Christopher Yip, Adriana Krizova, Jeffrey L. Wrana, Darren A. Yuen
Xiaolin He, Monica F. Tolosa, Tianzhou Zhang, Santosh Kumar Goru, Luisa Ulloa Severino, Paraish S. Misra, Caitríona M. McEvoy, Lauren Caldwell, Stephen G. Szeto, Feng Gao, Xiaolan Chen, Cassandra Atin, Victoria Ki, Noah Vukosa, Catherine Hu, Johnny Zhang, Christopher Yip, Adriana Krizova, Jeffrey L. Wrana, Darren A. Yuen
View: Text | PDF
Research Article Nephrology Pulmonology

Myofibroblast YAP/TAZ activation is a key step in organ fibrogenesis

  • Text
  • PDF
Abstract

Fibrotic diseases account for nearly half of all deaths in the developed world. Despite its importance, the pathogenesis of fibrosis remains poorly understood. Recently, the two mechanosensitive transcription cofactors YAP and TAZ have emerged as important profibrotic regulators in multiple murine tissues. Despite this growing recognition, a number of important questions remain unanswered, including which cell types require YAP/TAZ activation for fibrosis to occur and the time course of this activation. Here, we present a detailed analysis of the role that myofibroblast YAP and TAZ play in organ fibrosis and the kinetics of their activation. Using analyses of cells, as well as multiple murine and human tissues, we demonstrated that myofibroblast YAP and TAZ were activated early after organ injury and that this activation was sustained. We further demonstrated the critical importance of myofibroblast YAP/TAZ in driving progressive scarring in the kidney, lung, and liver, using multiple transgenic models in which YAP and TAZ were either deleted or hyperactivated. Taken together, these data establish the importance of early injury-induced myofibroblast YAP and TAZ activation as a key event driving fibrosis in multiple organs. This information should help guide the development of new antifibrotic YAP/TAZ inhibition strategies.

Authors

Xiaolin He, Monica F. Tolosa, Tianzhou Zhang, Santosh Kumar Goru, Luisa Ulloa Severino, Paraish S. Misra, Caitríona M. McEvoy, Lauren Caldwell, Stephen G. Szeto, Feng Gao, Xiaolan Chen, Cassandra Atin, Victoria Ki, Noah Vukosa, Catherine Hu, Johnny Zhang, Christopher Yip, Adriana Krizova, Jeffrey L. Wrana, Darren A. Yuen

×

Figure 5

Myofibroblast-specific YAP/TAZ deficiency attenuates bleomycin-induced lung and CCl4-induced liver fibrosis.

Options: View larger image (or click on image) Download as PowerPoint
Myofibroblast-specific YAP/TAZ deficiency attenuates bleomycin-induced l...
Myofibroblast-specific YAP/TAZ-deficient mice (Col1a1-Cre/ERT+/– Yapfl/fl Tazfl/fl) and their WT littermates (Col1a1-Cre/ERT–/– Yapfl/fl Tazfl/fl) were randomized to saline or bleomycin injections (n = 7 saline Col1a1-Cre/ERT–/– Yapfl/fl Tazfl/fl, n = 4 saline Col1a1-Cre/ERT+/– Yapfl/fl Tazfl/fl, n = 19 bleomycin Col1a1-Cre/ERT–/– Yapfl/fl Tazfl/fl, n = 10 bleomycin Col1a1-Cre/ERT+/– Yapfl/fl Tazfl/fl). Tamoxifen was administered between days 7 and 13 after saline/bleomycin injection, and lungs were harvested on day 14. (A) Arterial blood pO2 levels just prior to euthanization. Lung sections were stained with (B) H&E for Ashcroft injury scoring (a measure of lung fibrosis), or (C) an antibody directed against type 1 collagen. Scale bar: 100 μm. (D and E) Myofibroblast-specific YAP/TAZ-deficient mice (Col1a1-Cre/ERT+/– Yapfl/fl Tazfl/fl) and their WT littermates (Col1a1-Cre/ERT–/– Yapfl/fl Tazfl/fl) were randomized to corn oil (n = 8 Col1a1-Cre/ERT–/– Yapfl/fl Tazfl/fl and n = 4 Col1a1-Cre/ERT+/– Yapfl/fl Tazfl/fl) or CCl4 injections (n = 12 Col1a1-Cre/ERT–/– Yapfl/fl Tazfl/fl and n = 9 Col1a1-Cre/ERT+/– Yapfl/fl Tazfl/fl). Tamoxifen was administered between days 8 and 12 after the initiation of corn oil/CCl4 injections to activate expressed Cre recombinase. Livers were harvested 6 weeks after the first corn oil/CCl4 injection. Liver sections were stained with (D) picrosirius red (PSR) to label fibrillar collagen or (E) Masson’s trichrome to stain extracellular matrix. Scale bar: 100 μm. One-way ANOVA with post hoc Tukey’s test was used for comparisons. Data shown as mean ± SEM. *P < 0.05. pO2, partial pressure of oxygen; BLM, bleomycin.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts